Loading

Please wait...

Biktarvy

Generic Name: bictegravir, emtricitabine, and tenofovir (bik TEG ra vir, EM trye SYE ta been, and ten OF oh vir)
Brand Names: Biktarvy
Biktarvy (bictegravir, emtricitabine, tenofovir) is used to treat HIV-1 infection. Includes Biktarvy side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Biktarvy

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Biktarvy contains a combination of bictegravir, emtricitabine, and tenofovir. Bictegravir, emtricitabine, and tenofovir are antiviral medicines that prevent human immunodeficiency virus (HIV) from multiplying in your body. Biktarvy is used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). Biktarvy is for use in adults and children who weigh at least 55 pounds (25 kilograms). Biktarvy is not a cure for HIV or AIDS. Biktarvy may cause a serious condition called lactic acidosis. Too much lactic acid is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat. Learn more

Biktarvy Side Effects

Biktarvy Side Effects

Note: This document contains side effect information about bictegravir / emtricitabine / tenofovir alafenamide. Some of the dosage forms listed on this page may not apply to the brand name Biktarvy.

For the Consumer

Applies to bictegravir/emtricitabine/tenofovir alafenamide: oral tablet

Warning

Oral route (Tablet)

Warning: Post treatment acute exacerbation of hepatitis BSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of bictegravir/emtricitabine/tenofovir alafenamide.Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue bictegravir / emtricitabine / tenofovir alafenamide. If appropriate, anti-hepatitis B therapy may be warranted.

Along with its needed effects, bictegravir / emtricitabine / tenofovir alafenamide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking bictegravir / emtricitabine / tenofovir alafenamide:

Less common

  • Stomach pain

Rare

  • Changes in behavior
  • thoughts or attempts of killing oneself

Incidence not known

  • Bloody urine
  • dark urine
  • decreased appetite
  • decreased frequency or amount of urine
  • diarrhea
  • fast, shallow breathing
  • general feeling of discomfort
  • general tiredness and weakness
  • increased blood pressure
  • increased thirst
  • light-colored stools
  • loss of appetite
  • lower back or side pain
  • muscle pain or cramping
  • nausea
  • right upper abdominal pain and fullness
  • sleepiness
  • stomach discomfort
  • swelling of the face, fingers, or lower legs
  • troubled breathing
  • unusual tiredness or weakness
  • vomiting
  • weight gain
  • yellow eyes and skin

Some side effects of bictegravir / emtricitabine / tenofovir alafenamide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

  • Abnormal dreams
  • belching
  • bloated feeling
  • discouragement
  • dizziness
  • excess air or gas in the stomach or bowels
  • feeling of fullness
  • feeling sad or empty
  • headache
  • heartburn
  • indigestion
  • irritability
  • loss of interest or pleasure
  • passing gas
  • rash
  • stomach upset
  • trouble concentrating
  • trouble sleeping

For Healthcare Professionals

Applies to bictegravir / emtricitabine / tenofovir alafenamide: oral tablet

General

In clinical trials, the most common side effects reported were diarrhea, nausea, and headache. This drug was discontinued due to side effects in 1% of patients.

Hepatic

Elevated total bilirubin was reported in 15% of patients through week 96; grade 1 (1 to 1.5 times the upper limit of normal [1 to 1.5 x ULN]) and grade 2 (1.5 to 2.5 x ULN) increases were reported in 11% and 4% of patients, respectively. These increases were not associated with hepatic side effects or other liver-related laboratory abnormalities. Grade 3 bilirubin increases (not considered related to study drug) were reported in 4 patients using this drug (1%). No discontinuations due to hepatic side effects were reported through week 96 in clinical studies.

Elevated ALT (greater than 5 x ULN) and AST (greater than 5 x ULN) have each been reported in up to 2% of patients.

Out of 16 patients coinfected with HIV-1 and hepatitis B virus (HBV), hepatic flare (ALT greater than 10 x ULN) was reported in 1 patient; ALT returned to normal limits without interrupting therapy.

Severe acute exacerbations of hepatitis B (e.g., liver decompensation and liver failure) have been reported in patients coinfected with HIV-1 and HBV after discontinuation of products containing emtricitabine and/or tenofovir DF.

Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.

Very common (10% or more): Elevated total bilirubin (up to 15%)

Common (1% to 10%): Elevated AST, elevated ALT

Uncommon (0.1% to 1%): Hyperbilirubinemia

Frequency not reported: Hepatic flare

Emtricitabine and/or tenofovir disoproxil fumarate (DF):

-Frequency not reported: Severe hepatomegaly with steatosis, severe acute exacerbations of hepatitis B, liver decompensation, liver failure

Gastrointestinal

Common (1% to 10%): Diarrhea, nausea, elevated amylase

Uncommon (0.1% to 1%): Vomiting, flatulence, dyspepsia, abdominal pain

Elevated amylase (greater than 2 x ULN) was reported in 2% of patients.

Nervous system

Common (1% to 10%): Headache, dizziness

Musculoskeletal

Common (1% to 10%): Elevated creatine kinase

Frequency not reported: Osteonecrosis

Emtricitabine:

-Postmarketing reports: Arthralgia

Elevated creatine kinase (at least 10 x ULN) has been reported in 4% of patients.

Psychiatric

Suicidal ideation, suicide attempt, and depression suicidal were reported in less than 1% of patients; all events were serious and observed primarily in patients with history of depression, prior suicide attempt, or psychiatric illness.

Common (1% to 10%): Abnormal dreams, insomnia, depression

Uncommon (0.1% to 1%): Suicidal behavior, anxiety, sleep disorders

Frequency not reported: Suicidal ideation, suicide attempt, depression suicidal

Other

Common (1% to 10%): Fatigue, elevated low-density lipoprotein (LDL) cholesterol (fasted)

Antiretroviral therapy:

-Frequency not reported: Increased weight, increased blood lipids

Elevated LDL cholesterol (fasted) (greater than 190 mg/dL) has been reported in up to 3% of patients.

Hematologic

Decreased neutrophils (less than 750/mm3) have been reported in 2% of patients.

Common (1% to 10%): Decreased neutrophils

Emtricitabine:

-Uncommon (0.1% to 1%): Anemia

Renal

Increased serum creatinine occurred with bictegravir due to inhibition of tubular secretion of creatinine without affecting renal glomerular function. Increased serum creatinine was reported by 4 weeks of therapy and remained stable through 96 weeks; serum creatinine increased by 0.09 mg/dL from baseline to week 96. No discontinuations due to renal side effects were reported through week 96 in patients using this drug in clinical studies.

Renal impairment (including cases of acute renal failure and Fanconi syndrome) has been reported with the use of tenofovir prodrugs; no cases of Fanconi syndrome or proximal renal tubulopathy were reported in clinical trials of this drug.

Common (1% to 10%): Elevated serum creatinine

Tenofovir prodrugs:

-Frequency not reported: Renal impairment (including acute renal failure, Fanconi syndrome)

Dermatologic

Uncommon (0.1% to 1%): Rash, pruritus

Emtricitabine:

-Postmarketing reports: Angioedema

Tenofovir alafenamide-containing products:

-Postmarketing reports: Angioedema, urticaria

Metabolic

Emtricitabine and tenofovir DF:

-Frequency not reported: Lactic acidosis

Antiretroviral therapy:

-Frequency not reported: Increased glucose

Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.

Immunologic

Combination antiretroviral therapy:

-Frequency not reported: Immune reconstitution/reactivation syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Biktarvy